Cytokinetics
Update in progressCYTK (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing novel activators and inhibitors of muscle proteins to treat serious diseases in the United States. Its programs include MYQORZO, an oral cardiac myosin inhibitor for symptomatic oHCM; Aficamten, another cardiac myosin inhibitor for HCM; omecamtiv mecarbil for heart failure with reduced EF; Ulacamten for HFpEF (Phase 1); and CK-089, a fast skeletal troponin activator (Phase 1). Based in South San Francisco, CA, since 1997.
Company score
- Sentiment
- 0.47
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.44
- Governance
- 0.11
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.15
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.31
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEOMr. Robert I. Blum
- Founded1997
- Employees673
- Websitewww.cytokinetics.com
Identifiers
- ISINUS23282W6057
- FIGIBBG000F0R4N9
- LEI549300BE5DY1HW7IHA64
- CUSIP23282W100
- CIK0001061983